Drug tumor therapy

Until 2007, patients with metastatic renal cell carcinoma (RCC) were mainly treated with cytokines. The development of multikinase inhibitors and m-TOR inhibitors has revolutionized the treatment of metastatic RCC. Renal cell carcinoma is known to be resistant to chemotherapy and radiation. According to all current guidelines, metastatic renal cell carcinoma is treated in a risk-adapted manner. The so-called "Motzer criteria" of the MSKCC (Memorial Sloan Kettering Cancer Center) are used for this purpose (e.g. LDH, hemoglobin level, serum calcium, general condition, etc.). Patients with low- and intermediate-risk profiles are treated with sunitinib, bevacizumab plus interferon (IFN) and pazopanib after first-line therapy. The high-risk patients will receive temsirolimus.

As a second-line therapy, patients are recommended sorafenib, axitinib or pazopanib after prior treatment with cytokines. After prior treatment with VEGF receptor inhibitors, axitinib, sorafenib or everolimus is recommended. High-risk patients after temsirolimus should be included in a study, as there is still no clear recommendation for these patients.

Despite the tolerable side effect profile, close monitoring of the blood count, thyroid values, electrolytes, blood pressure measurement and, if necessary, a cardiac echo should be carried out.

We will be happy to advise you on this in our oncology consultation hours.